Volumen- und Blutkomponententherapie in der Intensivmedizin

  • C. von Heymann
  • O. Vargas Hein

Zusammenfassung

Das Ziel der Volumentherapie in der Intensivmedizin ist es, das Herzzeitvolumen zu normalisieren und die Mikrozirkulation zu optimieren.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Cochrane Injuries Group Albumine Reviewers (1998) Human albumine administration in critically ill patients: systematic review of randomized controlled trials. BMJ 317:235–240CrossRefGoogle Scholar
  2. 2.
    Treib J, Baron JF, Grauer MT, Strauss RG (1999) An international view of hydroxyethy starches. Intensive Care Med 25:258–268PubMedCrossRefGoogle Scholar
  3. 3.
    Boldt J (1998) Volumenersatz beim schwerkranken Intensivpatienten. Anästhesist 47: 778–785CrossRefGoogle Scholar
  4. 4.
    Hebert PC, Wells G, Blajchmann MA et al. (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340: 409–417PubMedCrossRefGoogle Scholar
  5. 5.
    Czer LS, Bateman TM, Gray RJ, Raymond M, Stewart ME, Lee S, Goldfinger D, Chaux A, Matloff JM (1987) Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Coll Cardiol 9 (5): 1139–1147PubMedCrossRefGoogle Scholar
  6. 6.
    McLeod BC (1990) Myocardial infarction in a blood donor after administration of desmopressin. Lancet 336 (8723): 1137–1138PubMedCrossRefGoogle Scholar
  7. 7.
    Levi M, Cromheecke ME, de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354:1940–1947Google Scholar
  8. 8.
    Herbert JM, Bernat A, Maffrand JP (1993) Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. Thromb Res 71 (6): 433–441PubMedCrossRefGoogle Scholar
  9. 9.
    Reininger AJ, Reininger CB, Spannagl M, Mellinghoff A, Porr A, Heinzmann U, Wurzinger U (1995) Effect of fibrinogen substitution in afibrinogenemia on hemorheology and platelet function. Thromb Haemost 74 (3): 853–858PubMedGoogle Scholar
  10. 10.
    Blauhut B (1999) Indications for prothrombin complex concentrates in massive transfusions. Thromb Res 95 (4 Suppl 1): S63-S69PubMedCrossRefGoogle Scholar
  11. 11.
    Warren BL, Eid A, Singer P et al. (2001) High-dose antithrom-bin III in severe sepsis. JAMA 286 (15): 1869–1878PubMedCrossRefGoogle Scholar
  12. 12.
    EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein llb/llla receptor in high-risk coronary angioplasty. New Engl J Med 330: 956–961CrossRefGoogle Scholar
  13. 13.
    The PURSUIT Triol Investigators (1998) Inhibition of platelet glycoprotein llb/llla with eptifibatide in patients with acute coronary syndromes. New Engl J Med 339: 436–443CrossRefGoogle Scholar
  14. 14.
    Topol EJ, TARGET Investigators (2001) Comparison of two platelet glycoprotein llb/llla inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New Engl J Med 344: 1937–1939CrossRefGoogle Scholar
  15. De Jonge E, Levi M (2001) Effects of different plasma substitutes on blood coagulation: A comparative review. Crit Care Med 29 (6): 1261–1267PubMedCrossRefGoogle Scholar
  16. Fourrier F, Jourdain M, Tournois A, Caron C, Goudemand J, Chopin C (1995) Coagulation inhibitor substitution during sepsis. Intensive Care Med 21 Suppl 2: S264-S268PubMedCrossRefGoogle Scholar
  17. Punjabi PP Wyse RK, Taylor KM (2000) Role of aprotinin in the management of patients during and after cardiac surgery. Expert Opin Pharmacother 1 (7): 1353–1365PubMedCrossRefGoogle Scholar
  18. Llau Pitarch JV, Diaz Alvarez A, Polonio Enriquez F, Castro Santamaria M, Ruiz Moyano J, Garcia Enguita MA (2000) Reduction of blood transfusion need with aprotinin in orthopedic surgery. Spanish Study Group on the Use of Aprotinin in Hip Arthroplasty (GEEEAAC). Rev Esp Anestesiol Reanim 47 (7): 309–316PubMedGoogle Scholar
  19. Staudinger T, Locker GJ, Frass M (1996) Management of acquired coagulation disorders in emergency and intensive-care medicine.-Semin Thromb Hemost 22 (1): 93–104CrossRefGoogle Scholar
  20. Menon V, Berkowitz SD, Antman EM, Fuchs RM, Hochman JS (2001) New heparin dosing recommendations for patients with acute coronary syndromes. Am J Med 110 (8): 641–650PubMedCrossRefGoogle Scholar
  21. Kaatz S (2000) The venous side: current directions in anticoagulant therapy. J Am Osteopath Assoc 100 (11 Suppl): S17-S21Google Scholar
  22. Fareed J, Callas D, Hoppensteadt DA, Walenga JM, Bick RL (1998) Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Med Clin North Am 82 (3): 569–586PubMedCrossRefGoogle Scholar
  23. Tsikouris JP, Tsikouris AP (2001) A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 21 (2): 207–217PubMedCrossRefGoogle Scholar
  24. Miller WL, Reeder GS (2001) Adjunctive therapies in the treatment of acute coronary syndromes. Mayo Clin Proc 76 (4): 391–405PubMedGoogle Scholar
  25. Baglin TP (2001) Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment J Clin Pathol 54 (4): 272–274PubMedCrossRefGoogle Scholar
  26. Kleinschmidt S, Seyfert UT (1999) Heparin-induced thrombocytopenia (HIT). Importance for anesthesia and intensive care. Anästhesist 11:771–785CrossRefGoogle Scholar
  27. Koster A, Meyer O, Hausmann H et al. (2000) In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery. J Clin An-esth 12 (4): 324–327CrossRefGoogle Scholar
  28. Vargas Hein O, von Heymann C, Lipps M et al. (2001) Hirudin vs. heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 27 (4): 673–679PubMedCrossRefGoogle Scholar
  29. Warkentin TE (1999) Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 82 (2): 439–447PubMedGoogle Scholar
  30. Warkentin TE; Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (17): 1286–1292PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • C. von Heymann
  • O. Vargas Hein

There are no affiliations available

Personalised recommendations